Otros idiomas Pharma Mar, S.A.

Acciones

PHM

ES0169501022

Farmacéuticos

Tiempo real estimado Tradegate Otros sitios de cotización 16:45:03 17/07/2026			Variación 5 días	Varia. 1 de enero.
75,42 ^EUR	-0,76 %		-4,00 %	+1,00 %

23/06	Merck solicita la autorización de comercialización en Japón para un tratamiento contra el cáncer de pulmón	MT
23/06	Bolsa española: factores a seguir el 23 de junio	RE

Otros idiomas

23/06	Merck Files Japanese Marketing Application for Lung Cancer Treatment
23/06	Spanish stocks - Factors to watch on June 23
22/06	PharmaMar Enrolls First Patient In Phase 1/2 Clinical Trial Evaluating PM54 In Combination With Pembrolizumab For Advanced Solid Tumors
16/06	Spanish stocks - Factors to watch on June 16
01/06	PharmaMar Announces European Commission Approves Zepzelca With Atezolizumab For Extended-Stage Small Cell Lung Cancer
01/06	Pharma Mar says EC approves Zepzelca with atezolizumab for first-line maintenance in SCLC
22/05	Spanish stocks - Factors to watch on May 22
21/05	Pharma Mar to propose dividend of 1.00 euro/shr
30/04	Spanish stocks - Factors to watch on April 30
30/04	Pharma Mar S A : Q126 (MARZO 2026 Informe Trimestral en GB)
30/04	Spanish stocks - Factors to watch on April 30
29/04	Pharma Mar Q1 EBITDA 2.7 mln euros
29/04	Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026
20/04	Specialised Therapeutics Announces Approval of Zepzelca in Combination with Atezolizumab as First-Line Maintenance Treatment for Extensive-Stage Small Cell Lung Cancer in Australia and Singapore
20/04	PharmaMar Says Small-Cell Lung Cancer Therapy Combo Secures Approval in Australia, Singapore
20/04	Pharma Mar's Zepzelca and Tecentriq combination gets approval in Australia and Singapore
27/03	EU Medicines Agency Backs Approval for Pharma Mar's Maintenance Drug for Extensive-stage Small Cell Lung Cancer
27/03	Pharma Mar receives positive opinion from EMA recommending approval of Zepzelca with atezolizumab
27/03	Pharma Mar completes acquisition of treasury shares for 7.0 mln euros
24/03	Pharma Mar S A : Non-Financial Information Statement (Consolidated non Financial Information Statement and Sustainability Information 2025 PharmaMar)
23/03	Pharma Mar gets Taiwan approval for its lung cancer treatment as first-line maintenance therapy
19/03	Globant And PharmaMar Form Strategic Alliance To Accelerate Oncology Research With AI
13/03	Pharma Mar S A : Consolidated Financial Statements and Consolidated Directors' Report (Consolidated Financial Statements and Consolidated Directors)
13/03	Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2025
12/03	Pharma Mar S A : Non-Financial Information Statement (Consolidated Non Financial Information Statement and Sustainability Information 2025 Pharma Mar)